Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma

Experimental and Molecular Pathology

Volumn 95, Issue 1, 2013, Pages 62-67

  Hudson, Jena ^a   Duncavage, Eric ^a   Tamburrino, Anna ^b   Salerno, Paolo ^b   Xi, Liqiang ^b   Raffeld, Mark ^b   Moley, Jeffrey ^a   Chernock, Rebecca D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Medullary thyroid carcinoma; MicroRNA; MiR 10a; MiR 375; MiR 455; YAP1

Indexed keywords

DNA; GROWTH INHIBITOR; MICRORNA; MICRORNA 10A; MICRORNA 375; MICRORNA 455; MONOCARBOXYLATE TRANSPORTER 8; RNA; UNCLASSIFIED DRUG; YAP1 PROTEIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; FAMILIAL CANCER; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RET GENE; THYROID MEDULLARY CARCINOMA; VALIDATION STUDY;

MEDULLARY THYROID CARCINOMA; MICRORNA; MIR-10A; MIR-375; MIR-455; YAP1;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; MUTATION; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-RET; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE VALUES; THYROID NEOPLASMS;

EID: 84879176399     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.05.001     Document Type: Article

References (33)

1. Abraham D., Jackson N., Gundara J.S., Zhao J., Gill A.J., Delbridge L., Robinson B.G., Sidhu S.B. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clinical Cancer Research 2011, 17:4772-4781.
2. Albores-Saavedra J., LiVolsi V.A., Williams E.D. Medullary carcinoma. Seminars in Diagnostic Pathology 1985, 2:137-146.
3. Boichard A., Croux L., Al Ghuzlan A., Broutin S., Dupuy C., Leboulleux S., Schlumberger M., Bidart J.M., Lacroix L. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. The Journal of Clinical Endocrinology and Metabolism 2012, 97:E2031-E2035.
4. Bottoni A., Piccin D., Tagliati F., Luchin A., Zatelli M.C., degli Uberti E.C. miR-15a and miR-16-1 down-regulation in pituitary adenomas. Journal of Cellular Physiology 2005, 204:280-285.
5. Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E., Wells S.A., Goodfellow P.J., Donis-Keller H. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:1579-1583.
6. Croce C. MicroRNAs in leukemia. Clinical Advances in Hematology & Oncology 2006, 4:577-578.
7. De Souza Rocha Simonini P., Breiling A., Gupta N., Malekpour M., Youns M., Omranipour R., Malekpour F., Volinia S., Croce C.M., Najmabadi H., Diederichs S., Sahin O., Mayer D., Lyko F., Hoheisel J.D., Riazalhosseini Y. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Research 2010, 70:9175-9184.
8. Foley N.H., Bray I., Watters K.M., Das S., Bryan K., Bernas T., Prehn J.H., Stallings R.L. MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death and Differentiation 2011, 18:1089-1098.
9. Garzon R., Fabbri M., Cimmino A., Calin G.A., Croce C.M. MicroRNA expression and function in cancer. Trends in Molecular Medicine 2006, 12:580-587.
10. Gilliland F.D., Hunt W.C., Morris D.M., Key C.R. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997, 79:564-573.
11. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., Hammond S.M. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
12. Kinne A., Schulein R., Krause G. Primary and secondary thyroid hormone transporters. Thyroid Research 2011, 4:S7. (Suppl. 1).
13. Kumar M.S., Erkeland S.J., Pester R.E., Chen C.Y., Ebert M.S., Sharp P.A., Jacks T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:3903-3908.
14. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
15. Liu N.-K., Xu X.-M. MicroRNA in central nervous system trauma and degenerative disorders. Physiological Genomics 2011, 43:571-580.
16. Liu J., Valencia-Sanchez M.A., Hannon G.J., Parker R. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nature Cell Biology 2005, 7:719-723.
17. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
18. Medina P.P., Nolde M., Slack F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467:86-90.
19. Mian C., Pennelli G., Fassan M., Balistreri M., Barollo S., Cavedon E., Galuppini F., Pizzi M., Vianello F., Pelizzo M.R., Girelli M.E., Rugge M., Opocher G. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid 2012, 22:890-896.
20. Modigliani E., Cohen R., Campos J.M., Conte-Devolx B., Maes B., Boneu A., Schlumberger M., Bigorgne J.C., Dumontier P., Leclerc L., Corcuff B., Guilhem I. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clinical Endocrinology 1998, 48:265-273.
21. Moura M.M., Cavaco B.M., Pinto A.E., Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. The Journal of Clinical Endocrinology and Metabolism 2011, 96:E863-E868.
22. Nikiforova M.N., Tseng G.C., Steward D., Diorio D., Nikiforov Y.E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. The Journal of Clinical Endocrinology and Metabolism 2008, 93:1600-1608.
23. Nikitina E.G., Urazova L.N., Stegny V.N. MicroRNAs and human cancer. Experimental Oncology 2012, 34:2-8.
24. Nishikawa E., Osada H., Okazaki Y., Arima C., Tomida S., Tatematsu Y., Taguchi A., Shimada Y., Yanagisawa K., Yatabe Y., Toyokuni S., Sekido Y., Takahashi T. miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. Cancer Research 2011, 71:6165-6173.
25. Ovcharenko D., Stolzel F., Poitz D., Fierro F., Schaich M., Neubauer A., Kelnar K., Davison T., Muller-Tidow C., Thiede C., Bornhauser M., Ehninger G., Brown D., Illmer T. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. Experimental Hematology 2011, 39:1030-1042. (e7).
26. Poy M.N., Hausser J., Trajkovski M., Braun M., Collins S., Rorsman P., Zavolan M., Stoffel M. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:5813-5818.
27. Sevignani C., Calin G.A., Siracusa L.D., Croce C.M. Mammalian microRNAs: a small world for fine-tuning gene expression. Mammalian Genome 2006, 17:189-202.
28. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., Mitsudomi T., Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Research 2004, 64:3753-3756.
29. Tamburrino A., Molinolo A.A., Salerno P., Chernock R.D., Raffeld M., Xi L., Gutkind J.S., Moley J.F., Wells S.A., Santoro M. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clinical Cancer Research 2012, 18:3532-3540.
30. Wells S.A., Santoro M. Targeting the RET pathway in thyroid cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15:7119-7123.
31. Xie X., Lu J., Kulbokas E.J., Golub T.R., Mootha V., Lindblad-Toh K., Lander E.S., Kellis M. Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 2005, 434:338-345.
32. Zeng Y., Yi R., Cullen B.R. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:9779-9784.
33. Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., Liang S., Naylor T.L., Barchetti A., Ward M.R., Yao G., Medina A., O'Brien-Jenkins A., Katsaros D., Hatzigeorgiou A., Gimotty P.A., Weber B.L., Coukos G. microRNAs exhibit high frequency genomic alterations in human cancer. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:9136-9141.